|
Andrea Easom, MA, MNSc, APN, BC, CNN
|
Andrea Easom, MA, MNSc, APN, BC, CNN, is
Clinical Instructor, University of Arkansas for
Medical Sciences, College of Medicine, Nephrology
Division, Little Rock, AR. She is a member of the
Arkansas Chapter of ANNA.
|
Expert guidelines recommend routine administration of intravenous iron therapy and frequent
monitoring of iron status for patients on hemodialysis who are being treated for anemia with
erythropoiesis-stimulating agents. However, monitoring iron status using conventional markers,
such as serum ferritin, may be complicated by acute and chronic inflammation and malnutrition,
which are common in this patient population. Therefore, nephrology nurses must be
knowledgeable of the limitations of using serum ferritin to assess iron status and how to interpret
high serum ferritin values to effectively treat patients on hemodialysis with anemia.
|
CE
RELATED INFORMATION |
|
This
offering for 1.4 contact
hours is being provided by
the
American
Nephrology Nurses Association
(ANNA), which
is accredited as a provider
and approver of continuing
education in nursing by
the American Nurses
Credentialing Center-Commission
on Accreditation (ANCCCOA).
This educational activity
is approved by most states
and specialty organizations
that recognize the ANCC-COA
accreditation process. ANNA
is an approved provider of
continuing education in nursing
by the California Board of
Registered Nursing, BRN Provider
No. 00910; and the Kansas
State Board of Nursing, Provider
No. LT0148-0738. This offering
is accepted for RN and LPN
relicensure in Kansas
|
|
Goal:
Nephrology nurses will be able to incorporate the 2006 KDOQI clinical practice
recommendations for iron administration into their anemia management practices.
Objectives:
1. Discuss the 2006 KDOQI clinical practice recommendations for target
ranges for serum ferritin levels and transferring saturation.
2. Describe reasons that serum ferritin is an imprecise measure of iron status.
3. List resources the nurse can employ to more accurately determine the
patient’s iron status.
|
AUTHOR DISCLOSURE
STATEMENT |
Andrea Easom
has no conflicts of interest to disclose.
|
ANNA and HDCN CE POLICY STATEMENTS |
The CE policy and disclosure statements of the American Nephrology
Nurses' Association are given in detail on the Symposium
Home Page. The CE policy statements of HDCN are listed on
this page. |